



Annual Report and Audited Financial Statements for the year ended 30 June 2023



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Contents	Page
General Information	3
Investment Manager's Report	4
Director's Report	5
Independent Auditor's Report	7
Custodian's Report	10
Supplementary Information	11
Portfolio Statement	12
Statement of Financial Position	14
Statement of Comprehensive Income	15
Statement of Cash Flows	16
Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares	17
Notes to the Financial Statements	18



Annual Report and Audited Financial Statements for the year ended 30 June 2023

General Information

Address and Registered Office

PO Box 255

Trafalgar Court, Les Banques St Peter Port, Guernsey

GY13QL

Channel Islands

Directors of the Incorporated Cell

Robert Alastair Rhodes

Roxanne Power

Marie Curutchet

Kapil Joshi - resigned 25 May 2023

Ray Mhere - appointed 25 May 2023

Investment Manager

Momentum Global Investment Management Limited

The Rex Building

62 Queen Street

London

EC4R 1EB

United Kingdom

Administrator, Registrar & Secretary

Northern Trust International Fund Administration

Services (Guernsey) Limited

PO Box 255

Trafalgar Court

Les Banques

St Peter Port, Guernsey

GY1 3QL

Channel Islands

Distribution Partner

FGAM (Pty) Limited

Lord Charles Office Park

337 Brooklyn Road

Building A Ground Floor

Brooklyn

Pretoria

Gauteng 0181, South Africa

Legal Advisor

Carey Olsen

Carey House

Les Banques

St Peter Port, Guernsey

GY1 4BZ

Channel Islands

Manager

Momentum Wealth International Limited

La Plaiderie House

La Plaiderie

St Peter Port, Guernsey

GY1 1WF

Channel Islands

Independent Auditor

Ernst & Young LLP

PO Box 9

Royal Chambers

St Julian's Avenue

St Peter Port, Guernsey

GY1 4AF

Channel Islands

Custodian

Northern Trust (Guernsey) Limited

PO Box 71

Trafalgar Court

Les Banques

St Peter Port, Guernsey

GY1 3DA

Channel Islands

Sub-Investment Manager

FGAM (Pty) Limited

Lord Charles Office Park

337 Brooklyn Road

Building A Ground Floor

Brooklyn

Pretoria

Gauteng 0181, South Africa



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Investment Manager's Report

Equity markets rallied during the second quarter as inflation eased, the United States Federal Reserve (the "Fed") paused rate hikes, the banking sector stabilised and technology stocks rebounded strongly.

Developed markets generated strong performance whilst emerging markets lagged, particularly China. Japan was the strongest performing region in local currency terms (up 14%) due to ongoing expectations of corporate governance reforms and structural shifts in the economy, combined with a weakening currency. The US was the next top performer (up 9%) with the majority of these gains coming from just seven mega-cap technology stocks which disproportionately benefitted from the hype around artificial intelligence ("AI"). Other factors driving positive returns in the region were the Fed's pause in June following ten consecutive interest rate hikes, and better than expected GDP growth.

Most sectors posted positive gains over the quarter but technology (14%) and consumer discretionary (10%) led the way. Utilities and energy (both down -1%) were the worst performing sectors and small-caps lagged large-caps which is unsurprising given the dominant performance of mega-cap technology.

Although Latin America posted strong gains during the period (14%), emerging market returns were muted (MSCI Emerging Markets up just 1% in dollar terms) because China is a large constituent and the region underperformed significantly (-10%). Key factors were the tensions between the US and China and fading optimism regarding China's recovery following the initial post-lockdown boom.

Global government bonds underperformed during the second quarter (-2%). With the exception of the Bank of Japan, all major central banks continued to raise interest rates in the fight to tame inflation. The Bank of England had to act aggressively, raising rates by 50bps as inflation is proving to be particularly sticky in the UK. The Fed decided to pause in June, raising hopes of a soft landing, however additional hikes are still expected.

Global high yield outperformed global investment grade as near-term recessionary fears abated and corporate balance sheets proved resilient for the most part.

The fund was flat to slightly down in the second quarter, in line with global bonds hedged into dollars. Our outlook, which focused on rate hikes by central banks and tighter-for-longer monetary policy, largely played out and the fund's underweight to duration therefore contributed positively to returns. However, our allocations to gold and the Japanese yen were both detractors, and in general our active equity managers struggled to add value relative to their benchmarks. The global equity index is currently skewed towards a small number of stocks within a single sector and with increasingly rich valuations. In order to overweight these mega-cap technology stocks, our managers would need to be heavily concentrated in one sector, which comes with risks. We switched part of our equity exposure into passive replication strategies at the start of April in order to partly offset the risk that active managers continue to struggle in this environment. More recently we've taken some profits on equity and also gold (with the gold price then around \$2,000) and added to the fund's duration as the yield on the US 10 year Treasury briefly spiked above 4%.

Over 12 months the Fund has returned 1.0%. Positioning within fixed income benefitted performance, in particular the fund's underweight to duration. The key detractor was manager selection within equity, foremost our quality managers Nedgroup and Morgan Stanley who both underperformed the MSCI World Index.

The manager line-up in the fund and the asset class mix continues to offer a good level of diversification that should see us through various market environments and cycles.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Directors' Report

The Directors present their annual report together with the audited financial statements of FGAM Global Cautious Fund IC Limited (the "Incorporated Cell" or "Cell") for the year ended 30 June 2023.

Principal activities

The Cell with company number 46258 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company"). The activities and objectives of the Cell can be found in note 1 page 18.

Going concern

The Directors have made an assessment of going concern including consideration of geo-political issues on the Cell. Refer to note 2 for the detailed disclosure.

Directors

The Directors of the Cell during the year and at the date of this report are set out on page 3.

Directors' interests

None of the Directors who held office during the year and at the date of this report had any disclosable interests in the shares of the Incorporated Cell.

Directors' responsibilities

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Incorporated Cell and of the profit or loss for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Incorporated Cell will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Incorporated Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020. They are also responsible for safeguarding the assets of the Incorporated Cell and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as each Director is aware, there is no relevant audit information of which the Incorporated Cell's auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Incorporated Cell's auditor is aware of that information.

The Board of Directors confirms that, throughout the period covered by the financial statements, the Cell complied with the Code of Corporate Governance issued by the Guernsey Financial Services Commission, to the extent it was applicable based upon its legal and operating structure and its nature, scale and complexity.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Directors' Report (continued)

The annual report together with the audited financial statements of the Incorporated Cells are published on the Manager's website. The Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website. The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent auditors

Ernst & Young LLP have indicated their willingness to continue in office. The reappointment of Ernst & Young LLP will be proposed within the next written resolution to deal with annual business.

Marie Curutchet

Director

30 November 2023

Robert Rhodes

Director



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Independent Auditor's Report to the Members of FGAM Global Cautious Fund IC Limited

Opinion

We have audited the financial statements of FGAM Global Cautious Fund IC Limited (the "Incorporated Cell") for the year ended 30 June 2023 which comprise the Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares, and the related notes 1 to 17, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- give a true and fair view of the state of the Incorporated Cell's affairs as at 30 June 2023 and of its profit for the year then ended;
- have been properly prepared in accordance with International Financial Reporting Standards; and
- have been properly prepared in accordance with the requirements of The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Incorporated Cell in accordance with the ethical requirements that are relevant to our audit of the financial statements, including the UK FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Incorporated Cell's ability to continue as a going concern for the period to 31 December 2024.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Incorporated Cell's ability to continue as a going concern.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Independent Auditor's Report to the Members of FGAM Global Cautious Fund IC Limited (continued)

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which The Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Incorporated Cell; or
- the financial statements are not in agreement with the Incorporated Cell's accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement set out on page 5, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Incorporated Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Incorporated Cell or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

- We obtained an understanding of the legal and regulatory frameworks that are applicable to the Incorporated Cell and determined that the most significant are those that relate to the reporting framework (International Financial Reporting Standards, The Companies (Guernsey) Law, 2008 and the Protection of Investors (Bailiwick of Guernsey) Law, 2020);
- We understood how the Incorporated Cell is complying with those frameworks by making enquiries of
 management and those responsible for compliance matters and corroborated this by reviewing minutes of
 meetings of the Board of Directors and correspondence between the Incorporated Cell and the Guernsey
 Financial Services Commission. We gained an understanding of the Board's approach to governance,
 demonstrated by its review of compliance reports, the investment manager's reports and internal control
 processes;



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Independent Auditor's Report to the Members of FGAM Global Cautious Fund IC Limited (continued)

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud (continued)

- We assessed the susceptibility of the Incorporated Cell's financial statements to material misstatement, including how fraud might occur by considering the risk of management override and by identifying the valuation of investments (specifically manual price overrides) and the recognition of dividend income at year-end (cut-off) as fraud risks. We considered the controls the Incorporated Cell has established to address the risk identified by the directors or that otherwise seek to prevent, detect or deter fraud and how management and those charged with governance monitor those controls. We also considered the existence of any stakeholder influences which may cause management to seek to manipulate the financial performance and did not note any;
- Based on this understanding we designed our audit procedures to identify non-compliance with such laws and
 regulations. Our procedures involved the review of minutes of meetings of the Board of Directors; review of
 compliance reports; review of correspondence with the Guernsey Financial Services Commission; making
 inquiries of those charged with governance; and performance of journal entry testing based on our risk
 assessment and understanding of the business, with a focus on non-standard journals and those relating to
 areas with an identified associated fraud risk, as described above.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the Incorporated Cell's members, as a body, in accordance with Section 262 of The Companies (Guernsey) Law 2008 and Paragraph 4.2(4) of the Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021. Our audit work has been undertaken so that we might state to the Incorporated Cell's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Incorporated Cell and the Incorporated Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

Ernst & Karrful

4753914588A54C3... Ernst & Young LLP

Guernsey, Channel Islands

Date: 04 December 2023



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Custodian's Report to the Members of FGAM Global Cautious Fund IC Limited

In our opinion, the Cell has, in all material aspects, been managed for the year ended 30 June 2023 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021.

For and on behalf of

Northern Trust (Guernsey) Limited

30 November 2023



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Supplementary Information

	30.06.23	30.06.22
NUMBER OF SHARES OUTSTANDING		
Class A	6,912,191	8,182,846
Class B	8,200,123	10,492,434
NET ASSET VALUE PER SHARE - USD		
Class A	1.23	1.21
Class B	1.10	1.09
HIGHEST/LOWEST PRICE - USD*		
Class A	1.24 / 1.12	1.42 / 1.20
Class B	1.12 / 1.00	1.27 / 1.08
NUMBER OF SHARES SUBSCRIBED		
Class A	624,830	581,274
Class B	200,743	627,081
NUMBER OF SHARES REDEEMED		
Class A	1,895,485	653,018
Class B	2,493,054	321,702

^{*}The highest/lowest price is based on prices from prior year end to current year end, being 30.06.2023.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Portfolio Statement

Holding	s Fair Value USD	% of Net Assets
Financial assets at fair value through profit or loss	<u>030</u>	
Collective Investment Schemes: 92.21% (2022: 91.51%)		
Commodity Funds		
iShares Physical Gold ETC 25,342	946,017	5.40
Total Commodity Funds	946,017	5.40
Equity Funds		
Artisan Global Value Fund 16,741	470,586	2.68
Fidelity Funds - Emerging Markets Fund 14,957	213,280	1.22
Fundsmith Equity Fund Feeder 12,250	414,983	2.37
iShares Core MSCI World UCITS ETF 4,210	354,735	2.02
iShares Edge MSCI World Value Factor UCITS ETF 9,000	340,113	1.94
iShares MSCI EM UCITS ETF USD Dist 900	34,972	0.20
Momentum GF Global Equity Fund 5,180	941,963	5.37
Morgan Stanley Investment Funds - Global Brands Fund 2,125	421,976	2.41
Nedgroup Investments Funds Global Equity Fund Class A 87,629	238,948	1.36
Orbis Global Equity Fund Class Shared Investor RRF 1,126	336,523	1.92
Sands Capital Funds - Sands Capital Global Growth Fund 10,595	426,026	2.43
Sands Capital Funds - Sands Emerging Markets Growth Fund 17,232	249,353	1.43
Total Equity Funds	4,443,458	25.35
Fixed Income Funds		
BlackRock Fixed Income Dublin Funds - US Corporate Bond Index Fund 60,850	1,033,532	5.90
BlackRock ICS Euro Ultra Short Bond Fund 3,973	450,347	2.57
Institutional Cash Series - Institutional Ultra Short Bond Fund 335	36,226	0.21
iShares \$ TIPS UCITS ETF 12,166	2,800,248	15.98
iShares \$ Treasury Bond 1-3yr UCITS ETF 348,834	1,823,704	10.40
iShares \$ Treasury Bond 3-7yr UCITS ETF 12,254	1,555,278	8.87
iShares \$ Treasury Bond 7-10yr UCITS ETF 2,180	383,636	2.19
Xtrackers II US Treasuries UCITS ETF 1D 13,830	2,689,907	15.34
Total Fixed Income Funds	10,772,878	61.46
Total Collective Investment Schemes	16,162,353	92.21



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Portfolio Statement (continued)

	Holdings	Fair Value	% of Net Assets
		<u>USD</u>	
Property and infrastructure Investment Trusts and ETFs: 6.86% (2022: 8.95	5%)		
Catalyst Global Real Estate Fund Class D	153,040	339,503	1.94
iShares Developed Markets Property Yield ETF USD Dist	9,700	211,460	1.20
Maple-Brown Abbott Global Infrastructure Fund	410,330	652,384	3.72
Total Property and infrastructure Investment Trusts and ETFs	-	1,203,347	6.86
Financial assets at fair value through profit or loss		17,365,700	99.07
Other Net Assets: 0.93% (2022: Liabilities 0.45%)		162,966	0.93
Net Assets Attributable To Holders of Participating Redeemable Shares		17,528,666	100.00



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Financial Position

Note	Year ended 30.06.23 es <u>USD</u>	Year ended 30.06.22 <u>USD</u>
ASSETS		
CURRENT ASSETS		
Financial assets at fair value through profit or loss 6	17,365,700	21,404,497
Cash and cash equivalents 7	274,487	18,885
Deposit interest receivable	250	-
Other receivables 8	468	547
Total assets	17,640,905	21,423,929
LIABILITIES		
CURRENT LIABILITIES		
Due on redemption of participating redeemable shares 3	-	529
Fair value of derivative financial instruments 9	85,295	86,461
Other payables 10	26,942	29,668
Liabilities (excluding net assets attributable to		
holders of participating redeemable shares)	112,237	116,658
Net assets attributable to holders of participating		
redeemable shares 3 & 2		21,307,269
Total liabilities	17,640,903	21,423,927
SHAREHOLDERS' EQUITY		
Management shares 11	2	2
Total equity	2	2
Total equity and liabilities	17 640 005	21 422 020
Total equity and liabilities	17,640,905	21,423,929
Net asset value per participating redeemable share 12		
Class A	1.23	1.21
Class B	1.10	1.09

The notes 1 to 17 on pages 18 to 34 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 30 November 2023 and signed on its

behalf by:

Marie Curutchet

Director

Robert Rhodes

Director



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Comprehensive Income

	•	Year ended Year ended	
		30.06.23	30.06.22
	Notes	<u>USD</u>	<u>USD</u>
INCOME			
Net realised (losses)/gains on financial assets at fair			
value through profit or loss	6	(136,979)	193,392
Change in unrealised gains/(losses) on financial assets at			
fair value through	6	539,995	(2,837,045)
Net gains/(losses) on financial assets at fair value through profit or loss		403,016	(2,643,653)
Deposit interest		1,366	(395)
Dividend income		74,498	15,981
Net loss on forward derivative contracts		(127,657)	(307,043)
Other foreign exchange gains		10,331	10,369
Otherincome	14 _	-	1,503
Total net income/(loss)	<u>-</u>	361,554	(2,923,238)
OPERATING EXPENSES			
Audit fee		(8,317)	(8,470)
Custodian fee	14	(9,845)	(13,867)
Investment Management fee	14	(96,501)	(129,855)
Management and Administration fee	14	(41,875)	(54,357)
Sundry expenses		(8,581)	(8,805)
Total operating expenses	=	(165,119)	(215,354)
Net profit/(loss) for the year		196,435	(3,138,592)
Increase/(decrease) in net assets attributable to holders	_	100 425	(2.120.502)
of participating redeemable shares from operations	=	196,435	(3,138,592)

All items in the above statement derive from continuing operations. There is no difference between the increase/(decrease) in net assets attributable to holders of participating redeemable shares and comprehensive income.

The notes 1 to 17 on pages 18 to 34 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Cash Flows

	Year ended 30.06.23 <u>USD</u>	Year ended 30.06.22 <u>USD</u>
CASH FLOW FROM OPERATING ACTIVITIES		
Increase/(decrease) in net assets attributable to holders of participating		
redeemable shares from operations	196,435	(3,138,592)
ADJUSTMENT FOR:		
Net realised losses/(gains) on financial assets at fair value through profit or loss	136,979	(193,392)
Net unrealised (gains)/losses on financial assets at fair value through profit or loss	(539,995)	2,837,045
Net losses on forward derivative contracts	127,657	307,043
Effect of foreign exchange rate on cash	(528)	-
Dividend income	(74,498)	(15,981)
Deposit interest	(1,366)	395
Operating loss before working capital changes	(155,316)	(203,482)
Net increase in other receivables	(171)	(97)
Net decrease in other payables	(2,726)	(7,151)
Purchase of financial assets at fair value through profit or loss	(7,598,736)	(7,131)
Sale of financial assets at fair value through profit or loss	12,040,549	7,165,874
Net settlement of forward derivative contracts	(128,823)	(259,460)
Dividend received	74,498	15,981
Deposit interest	1,366	(395)
Net cash generated from/(used in) operating activities	4,230,641	(1,026,467)
CASH FLOW FROM FINANCING ACTIVITIES	074 545	4 575 450
Cash received from issuance of participating redeemable shares	971,545	1,575,150
Cash paid on redemption of participating redeemable shares	(4,947,112)	(1,245,052)
Net cash (used in)/generated from financing activities	(3,975,567)	330,098
Net increase/(decrease) in cash and cash equivalents	255,074	(696,369)
Cash and cash equivalents at the beginning of the year	18,885	704,885
Effect of foreign exchange rate on cash	528	10,369
Cash and cash equivalents at the end of the year	274,487	18,885

The notes 1 to 17 on pages 18 to 34 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares

		Year ended 30.06.23	Year ended 30.06.22
	Notes	<u>USD</u>	<u>USD</u>
Net assets attributable to holders of participating redeemable shares			
at the beginning of the year		21,307,269	24,116,292
Proceeds from issuance of participating redeemable shares		971,545	1,575,150
Payments on redemption of participating redeemable shares		(4,946,583)	(1,245,581)
Increase/(decrease) in net assets attributable to holders of			
participating redeemable shares from operations		196,435	(3,138,592)
Net assets attributable to holders of participating redeemable shares	_		_
at the end of the year	12	17,528,666	21,307,269

The notes 1 to 17 on pages 18 to 34 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

1. General information

The FGAM Global Cautious Fund IC Limited (the "Incorporated Cell" or "Cell") with company number 46258 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company").

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager"), with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager") and FGAM (Pty) Ltd, acting as the Sub-Investment Manager.

The Cell's objective is capital preservation. A significant proportion of the portfolio will be held in the base currency and while the portfolio will invest in cash and bond investments, they will also invest into a wide range of other asset classes, in line with its investment objectives, including equities and property and so some degree of volatility is to be expected.

The Cell intends to achieve its investment objective by investing globally, primarily via other Collective Investment Schemes, in a wide range of asset classes including cash, bonds, property and equities. The Cell is suitable for investors with a time horizon of between 3 years or longer. The Cell may invest in the units of Collective Investment Schemes which are also managed by the Manager or an associate of the Manager. The Cell may invest in forward foreign currency exchange contracts to reduce its currency exposure.

No amendments were made to the Supplemental Prospectus of the Incorporated Cell during the year.

The financial statements were authorised for issue by the Board of Directors on 30 November 2023.

2. Summary of significant accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements.

2.1 Basis of preparation

The financial statements for the Incorporated Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards ("IFRS"). The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss (including derivative financial instruments).

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates, which are disclosed in note 4 of these Incorporated Cell's financial statements. It also requires the Board of Directors to exercise its judgement in the process of applying the Incorporated Cell's accounting policies.

Going concern

At the time of approving the financial statements, the Board has assessed redemption levels and there have been no significant redemptions. The Board has also considered the liquid nature of the investment portfolio, the absence of any borrowings or commitments and the economic viability of the Cell which is driven by its net asset value.

After careful consideration, the Board are satisfied that the Cell has sufficient liquidity to meet its liabilities for the period to 31 December 2024 and therefore it is appropriate to adopt the going concern basis in preparing the financial statements and they have a reasonable expectation that the Cell will continue in existence as a going concern.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

2. Summary of significant accounting policies (continued)

2.2 Adoption of new and revised standards

The Directors have adopted a policy of applying new standards and interpretations when they become effective.

Standards, amendments and interpretations effective during the year

The following accounting standards, amendments and interpretations became effective for the first time in this reporting period:

Periods beginning on or after 1 January 2022:

(a) IFRS 9 - Fees in the '10 per cent' Test for Derecognition of Financial Liabilities - Amendment to clarify the fees a company includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability.

The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

(b) IFRS 3 - Updating a Reference to the Conceptual Framework - Amendments updated IFRS 3 by replacing a reference to an old version of the Board's Conceptual Framework for Financial Reporting with a reference to the latest version. The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

Standards, amendments and interpretations in issue not yet effective

A number of new Standards, amendments and interpretations are effective for annual periods beginning on or after 1 January 2023 and have not been early adopted in preparing these financial statements. These include:

- (a) IAS 1 Definition of Accounting Estimates(Amendments to IAS 8) Effective from 1 January 2023 Amendments regarding classification of liabilities and disclosure of accounting policies.
- (b) IAS 1 Disclosure Initiative Accounting Policies Effective from 1 January 2023 Amendments to help entities apply materiality judgements to accounting policy disclosure.

The Board anticipates that the adoption of these standards, which will be adopted in the period which they become effective, will not have a material impact on the financial statements of the Cell.

2.3 Foreign currency translation

(a) Functional and presentation currency

The currency in which the financial information is shown in the financial statements of the Incorporated Cell is deemed to be its functional and presentational currency. In arriving at the functional currency, the Directors have considered the primary economic environment of the Incorporated Cell, and in doing so have considered the currency in which the original capital was raised, any distributions are to be made, performance is evaluated and ultimately, the currency in which capital would be returned on break up basis. They have also considered the currency to which the majority of the underlying investments are exposed and liquidity is managed. The Directors are of the opinion that the currency selected best represent the functional currency.

(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

2. Summary of significant accounting policies (continued)

2.4 Financial assets and financial liabilities at fair value through profit or loss

(a) Classification

The Incorporated Cell classifies its investments in Collective Investment Schemes, equities, and related derivatives as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are classified by the Board of Directors at fair value through profit or loss at inception. The Incorporated Cell does not classify any derivatives as hedges in a hedging relationship. Financial assets and financial liabilities are designated at fair value through profit or loss at inception, are managed, and their performance evaluated on a fair value basis in accordance with the Incorporated Cell's documented investment strategy. The Incorporated Cell's policies are for the Investment Manager and the Board of Directors to evaluate the information about these financial assets on a fair value basis together with other related financial information.

(b) Recognition/derecognition

Regular-way purchases and sales of investments are recognised on the trade date of the underlying security, so long as the underlying transaction has been confirmed by the relevant counterparty as at the Statement of Financial Position date. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Incorporated Cell has transferred substantially all risks and rewards of ownership.

(c) Measurement

Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed in the Statement of Comprehensive Income of the Incorporated Cell. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income in the period in which they arise.

(d) Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and trading securities) are based on quoted market prices at the close of trading on the reporting date. The Incorporated Cell adopted to utilise the last traded market price for both financial assets and financial liabilities where the last traded price falls within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the point within the bid-ask spread that is most representative of fair value. As a practical expedient to establish fair value within the bid-ask spread, management will use mid-market pricing. The market price used for assets which are not traded in active markets are those as supplied by their fund administrators.

2.5 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

2. Summary of significant accounting policies (continued)

2.6 Forward currency contracts

Forward foreign currency contracts are treated as derivative contracts and as such are recognised at fair value on the date on which they are entered into and subsequently remeasured at their fair value. Fair value is determined by rates in active currency markets. All derivatives are carried as assets when fair value is positive and as liabilities when fair value is negative. The gain or loss on remeasurement to fair value is recognised immediately through profit or loss in the Statement of Comprehensive Income within other losses and gains in the period in which they arise.

2.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts.

2.8 Other financial instruments

For other financial instruments, including amounts due to and from brokers and all receivables and payables, the carrying amounts as shown in the Statement of Financial Position approximate to fair value due to the short-term nature of these financial instruments.

2.9 Share capital

The Incorporated Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

(a) Management shares

Management shares were issued to comply with Guernsey Company Law, prior to its revision in 2008, under which there had to be a class of non-redeemable shares in issue in order that participating redeemable shares may be issued. The management shares are beneficially owned by the Manager, do not carry any right to dividends, are only entitled to vote at shareholder meetings where there are no participating redeemable shares in issue within the Incorporated Cell and are only entitled to return of capital on the winding up of the Incorporated Cell.

The Incorporated Cell has issued 2 management shares.

(b) Participating redeemable shares

The Incorporated Cell's capital is represented by participating redeemable shares with no par value each carrying one vote, no matter which share class. Each share class carries identical rights, the only difference between the classes being either the management fee or the distribution partner fee which is charged to each class. These fees are disclosed in note 14.

The participating redeemable shares are redeemable at the holder's option and are classified as financial liabilities. Participating redeemable shares can be put back to the Incorporated Cell at any time for cash equal to a proportionate share of the Incorporated Cell's net asset value. The participating redeemable share is carried at the redemption amount that is payable at the Statement of Financial Position date if the holder exercises the right to put the share back to the Incorporated Cell.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

2. Summary of significant accounting policies (continued)

2.9 Share capital (continued)

All participating redeemable shares will rank equally for all dividends and other distributions, as adjusted to reflect any differences in the fees to which each class of participating redeemable share is subject. They are entitled to payment of a proportionate share based on the Cell's net asset value per share on the redemption date. The Cell has no restrictions or specific capital requirements on the subscriptions and redemptions of shares. The relevant movements are shown on the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares. In accordance with the Cell's investment objectives, and its risk management policies, the Cell endeavours to invest the subscriptions received in appropriate investments while maintaining sufficient liquidity to meet redemptions, such liquidity being augmented by short-term borrowings or disposal of listed securities where necessary.

To determine the net asset value of the Cell for subscriptions and redemptions, investments have been valued based on the last traded market prices as of the close of business on the relevant trading day.

2.10 Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations

Income not distributed is included in Net Assets Attributable to Holders of Participating Redeemable Shares of the Incorporated Cell's financial statements.

2.11 Capital risk management

The fair value of the Cell's financial assets and financial liabilities approximate to their carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Incorporated Cell's objective when managing capital is to safeguard their ability to continue as a going concern in order to provide returns for shareholders. There are no externally imposed capital requirements on the Incorporated Cell. The Incorporated Cell has no intention to borrow, other than to fund short-term liquidity requirements. The Incorporated Cell may arrange an overdraft facility for such purposes.

2.12 Interest and dividend income

Dividend income is recognised when the right to receive payment is established. All deposit interest and other income is accounted for on an accruals basis.

2.13 Expenses

Expenses are accounted for on an accruals basis and all amounts have been allocated to the Statement of Comprehensive Income.

2.14 Custodian bank charges

Custodian bank charges include additional fees on top of the asking price of the security. The bid-asking spread is not disclosed as part of a custodian bank charge. This spread is included in the Statement of Comprehensive Income within the fair value net gain or loss.

2.15 Taxation

The Cell has been granted Exempt Status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,200 (2022: £1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are shown as a separate item in the Statement of Comprehensive Income.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

3. Financial risk management

3.1 Strategy in using financial instruments

The Cell's activities and investment objectives expose it to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the Cell is exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place throughout the year.

The Cell's policy allows it to use derivative financial instruments to both moderate and create certain risk exposure. The fair value of derivative financial instruments as at 30 June 2023 is disclosed under note 9 of these financial statements.

3.2 Market price risk

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in equities and Collective Investment Schemes. Through its investment in traded securities and instruments the Cell is subject to market movements in the equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions are monitored by the Investment Manager and are reviewed by the Board of Directors.

The Cell's market price risk is managed through diversification of the investment portfolio by exposure to varying product categories, hence concentration of risk is minimised. At the year end, the financial assets at fair value through profit or loss, which are subject to market price risk, are as follows:

	2023		2022	
		% of net		% of net
	Fair Value	assets	Fair Value	assets
	USD		<u>USD</u>	
Collective Investment Schemes	16,162,353	92.21	19,495,709	91.51
Property and Infrastructure Investment Trusts and ETFs	1,203,347	6.86	1,908,788	8.95
	17,365,700	99.07	21,404,497	100.46



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

3. Financial risk management(continued)

3.2 Market price risk (continued)

The Cell's market price risk is affected by three main components: changes in actual market prices, interest rate and foreign currency movements. Interest rate and foreign currency exchange rate movements are covered in notes 3.3 and 3.5, respectively. If the market indices increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2023	2022
	Change in	Change in
	fair value	fair value
	USD	<u>USD</u>
Collective Investment Schemes	1,616,235	1,949,571
Property and Infrastructure Investment Trusts and ETFs	120,335	190,879

3.3 Interest rate risk

The Cell's' interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

The table below summarises the Cell's exposure to interest rate risks. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual re-pricing or maturity dates within one month.

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
Net financial assets on which no interest is paid	17,253,929	21,288,384
Net floating rate financial assets	274,737	18,885

Should interest rates have increased/decreased by 50 basis points with all other variables remaining constant, the increase/decrease in the net assets attributable to participating redeemable shareholders would amount to approximately:

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
Movement in net floating rate financial assets	1,374	94

3.4 Cash flow risk

The Cell holds a significant amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

Financial risk management(continued) 5 Currency risk

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets including investments denominated in currencies other than the US Dollar, the functional currency, and therefore, it is exposed to currency risk. The exposures are based on the currencies of the underlying assets in the Cell. Where the Cell invests via Collective Investment Funds, the funds are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risk:

As at 30 June	2023	2022
	<u>USD</u>	USD
EUR exposure	37,769	4,241,379
ZAR exposure	(1,383)	-
GBP exposure	(6,290)	(5,108)
JPY exposure	(85,295)	(86,461)

In accordance with the Cell's policy, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk, however, to date the Investment Manager and Board of Directors have deemed that such contracts have not been necessary.

Should the Cell's functional currency have strengthened, or weakened, by 5% against other currencies to which it is exposed, and all other variables, including the price of all investments, had held constant, the net asset attributable to participating redeemable shareholders would have increased, or decreased, as follows:

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
EUR exposure	1,888	212,069
ZAR exposure	(69)	-
GBP exposure	(314)	(255)
JPY exposure	(4,265)	(4,323)

3.6 Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by the Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 3.2. No such redemption problems have been encountered.

All transactions in listed securities are settled or paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period, and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the Cell. Northern Trust (Guernsey) Limited is wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Cell's maximum exposure to credit risk is the carrying value of the assets on the Statement of Financial Position.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

3. Financial risk management(continued)

3.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradeable and have reported no warnings regarding their ability to process redemptions as normal.

The Cell has the ability to borrow to meet short term liquidity requirements, up to the value of 10% of the NAV of the Cell. To date the Cell has not had to enter into such arrangements.

The following table analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the Statement of Financial Position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.

	Less than	Between 1		
		and 12	2023	2022
	1 month	months	Total	Total
	<u>USD</u>	<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or				
loss	17,365,700	-	17,365,700	21,404,497
Cash and cash equivalents	274,487	-	274,487	18,885
Deposit interest	250	-	250	-
Other receivables	466	-	466	545
Fair value of derivative financial instruments	-	(85,295)	(85,295)	(86,461)
Due on redemption of participating				
redeemable shares	-	-	-	(529)
Other payables	(26,942)	-	(26,942)	(29,668)
Net assets attributable to holders of				
participating redeemable shares	(17,528,666)	-	(17,528,666)	(21,307,269)
Net liquidity position	85,295	(85,295)	-	_

Participating redeemable shares are redeemed on demand at the holder's option. However, the Board of Directors does not envisage that the contractual maturity disclosed in the table above will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.

3.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The Cell's overall strategy remains unchanged.

The Cell has no externally imposed capital requirements.

3.9 Fair value disclosure

In the opinion of the Directors, there are no material differences between the net asset values of the underlying assets and fair values of the financial assets and liabilities.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

4. Critical accounting estimates and judgements

The fair value of investments is considered to be the quoted, active market prices, or prices as supplied by the fund administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- · any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis. The Cell does not hold any Level 3 investments.

5. Portfolio analysis

The Cell's portfolio is organised by focusing on the type of security held, and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types which are disclosed in note 3.2 and the following main geographical areas:

	2023	2022
	<u>USD</u>	<u>USD</u>
Cayman Islands	1,749,072	2,765,590
Europe	13,044,555	15,512,764
Asia	2,322,719	2,808,627
Emerging Markets	249,354	317,516
	17,365,700	21,404,497

The geographical segment for listed non-monetary financial assets is considered to be the place of primary listing and for non-listed financial assets where the underlying investment is domiciled.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

6. Financial assets at fair value through profit or loss

	2023	2022
	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss:		
Collective Investment Schemes	16,162,353	19,495,709
Property and Infrastructure Investment Trusts and ETFs	1,203,347	1,908,788
Total financial assets at fair value through profit or loss	17,365,700	21,404,497
Movement on financial assets at fair value through profit or loss		
Fair value of financial assets at the beginning of the year	21,404,497	23,476,287
Purchases of financial assets	7,598,736	7,737,737
Sales of financial assets	(12,040,549)	(7,165,874)
Realised (losses)/gains on sale of financial assets	(136,979)	193,392
Movement in unrealised gains/(losses) on revaluation of financial assets	539,995	(2,837,045)
Fair value of financial assets at the end of the year	17,365,700	21,404,497
Comprising:		
Cost at the end of the year	16,299,059	20,877,851
Unrealised gains at the end of the year	1,066,641	526,646
	17,365,700	21,404,497

IFRS 13 requires the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety, is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Cell considers it to be the most advantageous market and would enter into transactions based on those prices.

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

6. Financial assets at fair value through profit or loss (continued)

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.

The following tables present the Cell's financial assets and financial liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2023 and 30 June 2022:

30 June 2023	Level 1 USD	Level 2 <u>USD</u>	Level 3 <u>USD</u>	Total <u>USD</u>
Financial assets at fair value through profit or loss				
Collective Investment Schemes	16,162,353	-	-	16,162,353
Property and Infrastructure Investment Trusts and ETFs	1,203,347	_	-	1,203,347
Financial liabilities at fair value through profit or loss				
Derivative financial instruments	-	(85,295)	-	(85,295)
	17,365,700	(85,295)	-	17,280,405
	Level 1	Level 2	Level 3	Total
30 June 2022	<u>USD</u>	<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss				
Collective Investment Schemes	19,495,709	_	_	19,495,709
Property and Infrastructure Investment Trusts and ETFs	1,908,788	_	_	1,908,788
Financial liabilities at fair value through profit or loss				
Derivative financial instruments		(86,461)	-	(86,461)
	21,404,497	(86,461)	-	21,318,036

The Cell's cash and cash equivalents and short-term receivables and payables are recorded at carrying value which approximates fair value.

There were no movements or reclassifications of investments within the levels of the fair value hierarchy during the years ended 30 June 2023 and 30 June 2022.

7. Cash and cash equivalents

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	2023	2022
	USD	<u>USD</u>
Cash at bank	274,487	18,885
	274,487	18,885
8. Other receivables		
	2023	2022
	<u>USD</u>	<u>USD</u>
Prepayments	466	545
Management shares receivables	2	2
	468	547



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

9. Fair value of derivative financial instruments

30 June 2023	Amount <u>CCY</u>	Maturity Date	Contracted rate	Closing rate	Contract value <u>USD</u>	Market value <u>USD</u>	Financial liabilities <u>USD</u>
Outstanding contract to buy JPY	JPY 140,000,000	10/08/2023	132.837500	144.535000	1,053,919	968,624 	(85,295) (85,295)
30 June 2022 Outstanding contract to	Amount <u>CCY</u>	Maturity Date	Contracted rate	Closing rate	Contract value <u>USD</u>	Market value <u>USD</u>	Financial liabilities <u>USD</u>

In accordance with the Cell's investment objectives, the Cell may enter into forward foreign exchange contracts to hedge foreign currency movements they may be exposed to through its investment portfolio. As there is no assurance that these hedges will be effective in achieving the offsetting of changes in cash flows attributable to currency risk on these investments, it is the policy of the Cell not to apply hedge accounting.

For foreign exchange contracts, the Cell pays a specified amount in one currency and receives a specified amount in another currency. Foreign exchange contracts are simultaneously settled gross and are presented on the Statement of Financial Position at their fair value.

10. Other payables

	2023	2022
	<u>USD</u>	<u>USD</u>
Management fee payable	4,026	4,452
Custodian fee payable	1,543	2,058
Investment Management fee payable	7,874	9,671
Audit fee payable	9,407	9,837
Sundry expenses payable	4,092	3,650
	26,942	29,668



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

11. Share Capital

The Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

Management shares in issue	2023 <u>USD</u>	2022 <u>USD</u>
Management shares	2	2
Participating Redeemable Shares in Issue - Class A	Year ended 30.06.23	Year ended 30.06.22
Balance at the beginning of the year	8,182,846	8,254,590
Issue of participating redeemable shares	624,830	581,274
Redemption of participating redeemable shares	(1,895,485)	(653,018)
Balance at the end of the year	6,912,191	8,182,846
Participating Redeemable Shares in Issue - Class B	Year ended 30.06.23	Year ended 30.06.22
Balance at the beginning of the year	10,492,434	10,187,055
Issue of participating redeemable shares	200,743	627,081
Redemption of participating redeemable shares	(2,493,054)	(321,702)
Balance at the end of the year	8,200,123	10,492,434

12. Net asset value per participating redeemable share

As at 30 June	NAV per share 2023 <u>USD</u>	Net assets attributable 2023 <u>USD</u>	Shares in issue 2023	NAV per share 2022 <u>USD</u>	Net assets attributable 2022 <u>USD</u>	Shares in issue 2022
Class A	1.23	8,470,650	6,912,191	1.21	9,894,317	8,182,846
Class B	1.10_	9,058,016	8,200,123	1.09	11,412,952	10,492,434
Total	_	17,528,666	15,112,314	_	21,307,269	18,675,280

13. Dividends payable to participating redeemable shareholders

The Directors are entitled to, but shall not be obliged to, distribute available income (consisting of all dividends, interest and other income) received net of expenses, of the Cell by way of dividends. Such dividends, if declared will usually be paid in August and February. No dividends were paid during the year (2022: Nil).



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

14. Related-party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

14.1 Management and Administration fee

The Cell is managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place.

Pursuant to the Management Agreement, the Manager shall be entitled to the payment of a fee (the "Management and Administration fee") for the services rendered in connection with the Cell. The Management and Administration fee will accrue as at each Valuation Point, based on the current aggregate valuation of the Cell of the Company in respect of which the Distribution Partner is appointed, and is payable monthly in arrears.

The Management and Administration fee will be chargeable on a sliding scale as follows and is subject to a minimum annual fee of USD22,000.

Fee - % of NAV per annum	<u>Cell NAV</u>
0.25%	On assets between US\$0 and US\$30m
0.23%	On the amount between US\$30m and US\$60m
0.20%	On the amount above US\$60m

The Administrator is entitled to such remuneration as agreed between the Manager and the Administrator from time to time and such remuneration is paid by the Manager out of the Management and Administration fee received from the Cell.

Management and Administration fee charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	41,875	54,357
Accrued at year end	4,026	4,452
Management fee rebate received during the year:		
	2023	2022
	<u>USD</u>	<u>USD</u>
Received during the year	-	1,503

14.2 Investment Management fee

Pursuant to the Investment Management Agreement, Momentum Global Investment Management Limited (the "Investment Manager"), is entitled to receive a fee (the "Investment Management fee") for services rendered in connection with the Cell. The Investment Management Fee will accrue as each Valuation Point, based on the current aggregate valuation of all Cells of the Company and is payable monthly in arrears.

In respect of the Class A USD Shares, the Investment Management fee will be chargeable on the sliding scale below, and will be borne by the Class A USD Shares on a pro rata basis by reference to the proportion of the NAV of the Class A USD Shares in the aggregate NAV of the FGAM Cells:

Fee - % of NAV per annum	<u>Cell NAV</u>
0.65%	On assets between US\$0 and US\$100m

0.575%

On the amount above US\$100m



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

14. Related-party transactions (continued)

14.2 Investment Management fee (continued)

In respect of the Class B USD Shares, the Investment Management fee will be chargeable on the sliding scale below, and will be borne by the Class B USD Shares on a pro rata basis by reference to the proportion of the NAV of the Class B USD Shares in the aggregate NAV of the FGAM Cells:

Fee - % of NAV per annumCell NAV0.45%On assets between US\$0 and US\$100m0.375%On the amount above US\$100m

Investment Management fees charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	96,501	129,855
Accrued at year end	7,874	9,671

14.3 Sub-Investment Management fee

The Investment Manager has appointed FGAM (Pty) Ltd, a South African registered company, as Sub-Investment Manager to the Cell (the "Sub-Investment Manager"). In respect of the Class A USD Shares, the Sub-Investment Manager is entitled to receive a fee of 0.50% of the NAV of the Cell per annum the "Sub-Investment Management fee". In respect of the Class B USD Shares the Sub-Investment Manager is entitled to receive a fee of 0.30% of the NAV of the Cell per annum. In both cases the fee will be paid out of the fee received by the Investment Manager. The Sub-Investment Management fee will accrue as at each Valuation Point, based on the current valuation and is payable monthly in arrears.

14.4 Custodian fee

The Cell has engaged the services of Northern Trust (Guernsey) Limited to provide custodian services. The custodian is entitled to the payment of a fee (the "Custody fee") chargeable on a sliding scale in respect of all Share classes, as follows, subject to a minimum of USD8,000 per annum.

Fee - % of NAV per annum	<u>Cell NAV</u>
0.05%	On assets between US\$0 and US\$30m
0.04%	On the amount between US\$30m and US\$60m
0.03%	On the amount above US\$60m
0.02%	On the amount above US\$100m

Custodian fees charged and accrued at the year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	9,845	13,867
Accrued at year end	1,543	2,058

14.5 Distribution Partner's fee

The Cell has appointed FGAM (Pty) Ltd as distribution partner to promote and market the Cell. The Distribution Partner will not be paid a fee.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Notes to the Financial Statements

14. Related-party transactions (continued)

14.6 Board of Directors' remuneration

The Directors' fees in respect of the Cell shall not exceed USD20,000 or currency equivalent in any 12-month period. In addition, the Directors shall be entitled to be repaid for all reasonable out of pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of the Cell alone and not from the cellular assets of other Cells of the Company or assets of the Company itself.

The Directors waived their right to a fee in 2023 (2022: Nil).

15. Ultimate controlling party

In the opinion of the Directors, on the basis of the shareholdings advised to them, the Cell has no ultimate controlling party.

16. Reconciliation of published valuation to financial statements

	2023	2022
	<u>USD</u>	<u>USD</u>
Net assets attributable to holders of participating redeemable shares per		
financial statements	17,528,666	21,307,269
Adjustments:		
Adjustment in value of assets at financial assets at fair value through profit or loss	(31,620)	34,860
Adjustment in value of derivative financial assets	5,119	3,774
Adjustment to accrue for rebranding of financial statements	-	441
Net assets attributable to holders of participating redeemable shares per		_
published valuation	17,502,165	21,346,344
NAV per Class A share per published valuation	1.22	1.21
NAV per Class B share per published valuation	1.10	1.09
NAV per Class A share per financial statements	1.23	1.21
NAV per Class B share per financial statements	1.10	1.09

17. Subsequent events

These financial statements were approved for issuance by the Board on 30 November 2023. Subsequent events have been evaluated until this date.

No significant subsequent events have occurred in respect of the Cell that are considered material to the understanding of these audited financial statements.